On 28 January, the Taskforce of the Beneluxa Initiative entitled “Domain Taskforce Horizon Scanning” published a report on pharmaceutical developments on Alzheimer’s disease (AD) for Austria, Belgium, Ireland, Luxembourg and the Netherlands. The aim of the Beneluxa Initiative is to ensure sustainable access to innovative medicine at affordable cost for patients in the represented countries.
The report gives an overview of new pharmaceutical developments, lists the current treatment options, gives an overview of the estimates of the prevalence of dementia as well as the available guidelines and an estimation of the current pharmaceutical costs for this disease in the Beneluxa countries. The main focus of the report is on the new pharmaceuticals that could enter the market between 2022 and 2027.
The setup of the clinical trials, including the used biomarkers, are summarised. Also, the possible challenges, both on HTA level as on Health care level, are described. With this report, Beneluxa aims to timely inform policy makers, healthcare organizations, payers and the general public on upcoming new pharmaceuticals and possible challenges. The report can be downloaded here:
https://beneluxa.org/sites/beneluxa.org/files/2022-01/Beneluxa_Alzheimer%27s_Disease_Jan2022.pdf
